Humacyte (HUMA) vs Molecular Partners (MOLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Molecular Partners (MOLN) has outperformed Humacyte (HUMA) over the past year, gaining 2.7% versus a loss of 71.3%. Over five years, MOLN leads with a -80.8% price change compared with -95.4% for HUMA. Molecular Partners is the larger company by market cap ($145.9 million vs $131.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUMA | MOLN |
|---|---|---|
| Share price | $0.4723 | $3.81 |
| Market cap | $131.20M | $145.94M |
| 1-day change | -1.19% | +0.79% |
| YTD return | -50.85% | -12.59% |
| 1-year return | -71.29% | +2.70% |
| 5-year return | -95.38% | -80.76% |
| EPS (TTM) | $-0.51 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.90 | $5.36 |
| 52-week low | $0.46 | $3.53 |
| Distance from 52-week high | -75.08% | -28.92% |
| Average volume | 6.35M | 1.19K |
| Shares outstanding | 277.80M | 38.31M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MOLN has outperformed HUMA by 74.0 percentage points over the past year.
HUMA vs MOLN FAQ
Which is bigger, Humacyte or Molecular Partners?
Molecular Partners (MOLN) is larger, with a market capitalization of $145.94M compared with $131.20M for Humacyte (HUMA).
Which stock has performed better over the past year, HUMA or MOLN?
MOLN returned +2.70% over the past 12 months, compared with -71.29% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Humacyte and Molecular Partners in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.